메뉴 건너뛰기




Volumn 52, Issue 8-9, 2012, Pages 776-787

Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: Perspective and results

Author keywords

Antitumor agents; Cancer; Epidermal growth factor receptor; Photodynamic therapy; Photoimmunoconjugates

Indexed keywords


EID: 84870595559     PISSN: 00212148     EISSN: 18695868     Source Type: Journal    
DOI: 10.1002/ijch.201200016     Document Type: Review
Times cited : (34)

References (145)
  • 6
    • 42249094731 scopus 로고    scopus 로고
    • M. Markman, Drugs 2008, 68, 771.
    • (2008) Drugs , vol.68 , pp. 771
    • Markman, M.1
  • 32
    • 84870611594 scopus 로고    scopus 로고
    • VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer" [Clinical- Trials.gov identifier NCT00436501] US National Institutes of Health, as accessed on the website: , last accessed on 07/31/2012
    • M. D. Anderson Cancer Center, National Cancer Institute, "VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer" [Clinical- Trials.gov identifier NCT00436501], US National Institutes of Health, as accessed on the website: http://clinicaltrials. gov/ct2/show/NCT00436501, last accessed on 07/31/2012.
    • Cancer Center, National Cancer Institute
    • Anderson, M.D.1
  • 37
    • 84870626934 scopus 로고    scopus 로고
    • Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer (SaPPrOC)" [ClinicalTrials.gov identifier NCT01196741] US National Institutes of Health, as accessed on the website: , last accessed on 07/31/2012
    • University College London, AstraZeneca, Cancer Research UK, "Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer (SaPPrOC)" [ClinicalTrials.gov identifier NCT01196741], US National Institutes of Health, as accessed on the website: http://clinicaltrials.gov/ct2/ show/ NCT01196741, last accessed on 07/31/2012.
    • University College London, AstraZeneca, Cancer Research UK
  • 38
    • 85030949372 scopus 로고    scopus 로고
    • Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies" [ClinicalTrials.gov identifier NCT00703170] US National Institutes of Health, as accessed on the website, last accessed on 07/31/2012
    • Washington University School of Medicine, "Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies" [ClinicalTrials.gov identifier NCT00703170], US National Institutes of Health, as accessed on the website: http://clinicaltrials.gov/ct2/show/NCT00703170, last accessed on 07/31/2012.
    • Washington University School of Medicine
  • 39
    • 84870595378 scopus 로고    scopus 로고
    • PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic" [ClinicalTrials.gov identifier NCT01540253] US National Institutes of Health, as accessed on the website: , last accessed on 07/31/2012
    • Roswell Park Cancer Institute, National Cancer Institute, "PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic" [ClinicalTrials.gov identifier NCT01540253], US National Institutes of Health, as accessed on the website: http:// clinicaltrials.gov/ct2/show/NCT01540253, last accessed on 07/31/2012.
    • Roswell Park Cancer Institute National Cancer Institute
  • 40
    • 84870619077 scopus 로고    scopus 로고
    • Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors" [ClinicalTrials.gov identifier NCT00313599] US National Institutes of Health, as accessed on the website: , last accessed on 07/31/2012
    • University of California San Francisco, National Cancer Institute, "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors" [ClinicalTrials.gov identifier NCT00313599], US National Institutes of Health, as accessed on the website: http://clinicaltrials.gov/ct2/show/ NCT00313599, last accessed on 07/31/2012.
    • University of California San Francisco, National Cancer Institute
  • 41
    • 84870603159 scopus 로고    scopus 로고
    • Sanofi-Aventis Walther Cancer Institute "Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum- Refractory Ovarian Cancer" [ClinicalTrials.gov identifier NCT00216112] US National Institutes of Health, as accessed on the website: , last accessed on 07/31/2012
    • Hoosier Oncology Group, Novartis Pharmaceuticals, Sanofi-Aventis, Walther Cancer Institute, "Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum- Refractory Ovarian Cancer" [ClinicalTrials.gov identifier NCT00216112], US National Institutes of Health, as accessed on the website: http://clinicaltrials.gov/ct2/show/ NCT00216112, last accessed on 07/31/2012.
    • Hoosier Oncology Group, Novartis Pharmaceuticals
  • 71
  • 108
    • 33745227821 scopus 로고    scopus 로고
    • Eds.: D. Kufe, R. Bast, W. Hait, W. Hong, R. Pollock, R. Weichselbaum, J. Holland, E. Frei) 7th edition, B C. Decker, Inc., Hamilton, Ontario
    • T. Hasan, B. Ortel, N. Solban, B.W. Pogue, in Cancer Medicine (Eds.: D. Kufe, R. Bast, W. Hait, W. Hong, R. Pollock, R. Weichselbaum, J. Holland, E. Frei), 7th edition, B. C. Decker, Inc., Hamilton, Ontario, 2006, pp. 537-548.
    • (2006) Cancer Medicine , pp. 537-548
    • Hasan, T.1    Ortel, B.2    Solban, N.3    Pogue, B.W.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.